VACCITECH (SP.ADR)/1 (2AB) - Total Assets
Based on the latest financial reports, VACCITECH (SP.ADR)/1 (2AB) holds total assets worth €92.14 Million EUR (≈ $107.72 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
VACCITECH (SP.ADR)/1 - Total Assets Trend (2021–2025)
This chart illustrates how VACCITECH (SP.ADR)/1's total assets have evolved over time, based on quarterly financial data. Also see 2AB market cap overview for the company's overall valuation and market capitalisation.
VACCITECH (SP.ADR)/1 - Asset Composition Analysis
Current Asset Composition (December 2025)
VACCITECH (SP.ADR)/1's total assets of €92.14 Million consist of 79.2% current assets and 20.8% non-current assets. Review VACCITECH (SP.ADR)/1 (2AB) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 71.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how VACCITECH (SP.ADR)/1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 2AB share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VACCITECH (SP.ADR)/1's current assets represent 79.2% of total assets in 2025, a decrease from 80.8% in 2021.
- Cash Position: Cash and equivalents constituted 71.8% of total assets in 2025, down from 76.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
VACCITECH (SP.ADR)/1 Competitors by Total Assets
Key competitors of VACCITECH (SP.ADR)/1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
VACCITECH (SP.ADR)/1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.05 | 9.18 | 8.93 |
| Quick Ratio | 6.05 | 9.18 | 8.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €60.66 Million | €97.91 Million | €119.58 Million |
VACCITECH (SP.ADR)/1 - Advanced Valuation Insights
This section examines the relationship between VACCITECH (SP.ADR)/1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -38.8% |
| Total Assets | €98.17 Million |
| Market Capitalization | $20.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values VACCITECH (SP.ADR)/1's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: VACCITECH (SP.ADR)/1's assets decreased by 38.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for VACCITECH (SP.ADR)/1 (2021–2025)
The table below shows the annual total assets of VACCITECH (SP.ADR)/1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €98.17 Million ≈ $114.77 Million |
-38.77% |
| 2024-12-31 | €160.33 Million ≈ $187.44 Million |
-25.26% |
| 2023-12-31 | €214.51 Million ≈ $250.78 Million |
-20.61% |
| 2022-12-31 | €270.20 Million ≈ $315.90 Million |
-3.74% |
| 2021-12-31 | €280.71 Million ≈ $328.19 Million |
-- |
About VACCITECH (SP.ADR)/1
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more